Online citations, reference lists, and bibliographies.
← Back to Search

Biofunctionalized Targeted Nanoparticles For Therapeutic Applications

A. Wang, F. Gu, L. Zhang, Juliana M. Chan, A. Radovic-Moreno, Mariam R Shaikh, O. Farokhzad
Published 2008 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Background: The development of nanoparticles for the delivery of therapeutic agents has introduced new opportunities for the improvement of medical treatment. Recent efforts have focused on developing targeted nanoparticles, which are formulated by (for therapeutic delivery) functionalizing nanoparticle surfaces with targeting molecules, such as antibodies, peptides, small molecules and oligonucleotides. Objectives: To review the state of targeted nanoparticles development. Methods: The authors discuss the nanoparticle platforms for therapeutic delivery, targeting molecules and the biofunctionalized targeted nanoparticles currently in development. Results/conclusions: Biofunctionalized targeted nanoparticles have demonstrated exciting results in preclinical studies. With continued improvements, they may fulfill their potential as therapeutics carriers that can deliver the maximum dose to diseased tissue while minimizing effects on normal cells.
This paper references
10.1161/CIRCULATIONAHA.106.619056
Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo
J. Deguchi (2006)
10.1038/263797A0
Polymers for the sustained release of proteins and other macromolecules
R. Langer (1976)
10.1016/S0169-409X(02)00021-2
The origin of pegnology.
F. F. Davis (2002)
10.1073/pnas.2232479100
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance
L. R. Hirsch (2003)
Designer genes: recombinant antibody fragments for biological imaging.
A. Wu (2000)
10.1002/cncr.10201
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
10.1016/J.IJPHARM.2003.09.050
Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME).
T. Tanaka (2004)
10.1007/s10555-005-6196-y
Development and regulation of monoclonal antibody products: Challenges and opportunities
W. Weinberg (2005)
10.1056/NEJMOA021491
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
J. Yang (2003)
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
J. Park (2002)
10.1038/nrc1958
Polymer conjugates as anticancer nanomedicines
R. Duncan (2006)
10.1016/J.COPBIO.2006.10.003
Biopharmaceutical drug discovery using novel protein scaffolds.
Davinder S Gill (2006)
Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.
S. Hu (1996)
10.1038/nbt1006-1211
The emerging nanomedicine landscape
Volker Wagner (2006)
10.1016/0022-2836(91)90509-5
SELEXION. Systematic evolution of ligands by exponential enrichment with integrated optimization by non-linear analysis.
D. Irvine (1991)
10.1158/0008-5472.CAN-05-4199
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
D. Kirpotin (2006)
Drug delivery and targeting.
R. Langer (1998)
10.1080/10611860701231810
Targeted nanoparticle-based drug delivery and diagnosis
D. Emerich (2007)
10.1016/0142-9612(91)90107-L
Controlled and modulated release of basic fibroblast growth factor.
E. Edelman (1991)
10.1021/LA0502084
Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate.
S. H. Kim (2005)
10.1158/0008-5472.CAN-04-3921
Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.
J. Kukowska-Latallo (2005)
10.1038/nrd1632
Recent advances with liposomes as pharmaceutical carriers
V. Torchilin (2005)
10.1089/CBR.2005.20.239
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.
Ann-Charlott Steffen (2005)
10.1200/JCO.2005.10.017
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
H. Hurwitz (2005)
10.1016/S0168-3659(01)00397-2
Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA.
C. Pérez (2001)
10.1038/347406A0
In vitro genetic analysis of the Tetrahymena self-splicing intron
R. Green (1990)
10.1016/S1380-2933(98)00026-8
An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein.
M. Hansson (1999)
10.1016/1074-5521(95)90032-2
Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor.
L. Green (1995)
10.1126/SCIENCE.8128245
Biodegradable long-circulating polymeric nanospheres.
R. Gref (1994)
10.1023/A:1011922819926
Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration
M. Tobío (2004)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
10.1016/J.JCIS.2006.03.005
Preparation and characterization of carbonyl iron/poly(butylcyanoacrylate) core/shell nanoparticles.
J. L. Arias (2006)
10.1016/S0168-3659(02)00009-3
Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery.
A. Kabanov (2002)
Nanotechnology based drug delivery system(s) for the management of tuberculosis.
R. Pandey (2006)
10.1126/SCIENCE.2218494
New methods of drug delivery.
R. Langer (1990)
10.1038/nature02388
Designing materials for biology and medicine
R. Langer (2004)
10.1038/355850A0
Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures
A. Ellington (1992)
10.2174/138945006777435245
Nanoparticle-based diagnosis and therapy.
D. Groneberg (2006)
10.1038/NMAT1045
Controlled assembly of dendrimer-like DNA
Y. Li (2004)
10.1021/NL051264S
Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology.
A. Khaled (2005)
10.1158/0008-5472.CAN-03-3935
Efficient cancer therapy with a nanobody-based conjugate.
Virna Cortez-retamozo (2004)
10.1038/nbt1320
Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting
Xiaoqing Qiu (2007)
10.1074/jbc.273.32.20556
2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165)
J. Ruckman (1998)
10.3816/CGC.2006.N.012
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
K. Beekman (2006)
10.1056/NEJMOA052122
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
10.1021/CR970069Y
About Dendrimers: Structure, Physical Properties, and Applications.
A. W. Bosman (1999)
10.1056/NEJMOA011795
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
B. E. C. Oiffier (2002)
10.1016/0022-2836(92)90870-P
Selection of high affinity RNA ligands to the bacteriophage R17 coat protein.
D. Schneider (1992)
10.1126/SCIENCE.2200121
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.
C. Tuerk (1990)
10.1517/14728222.8.4.335
Development of ligand-targeted liposomes for cancer therapy
C. Noble (2004)
10.1073/pnas.0711714105
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers
F. Gu (2008)
10.1016/S0169-409X(02)00042-X
Folate-mediated delivery of macromolecular anticancer therapeutic agents.
Y. Lu (2002)
10.1016/J.ADDR.2005.09.018
Dendrimers in biomedical applications--reflections on the field.
Sönke Svenson (2005)
10.1146/ANNUREV.BIOCHEM.68.1.611
In vitro selection of functional nucleic acids.
D. Wilson (1999)
10.1385/MB:27:1:59
Preclinical safety testing of biotechnology-derived pharmaceuticals
F. R. Brennan (2004)
10.1200/JCO.1995.13.7.1777
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
B. Uziely (1995)
10.1073/PNAS.0601755103
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
O. Farokhzad (2006)
10.1016/J.JCONREL.2004.01.002
Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice.
M. Oyewumi (2004)
10.1073/PNAS.83.12.4223
Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor.
J. Tschopp (1986)
10.1158/0008-5472.CAN-04-2550
Nanoparticle-Aptamer Bioconjugates
O. Farokhzad (2004)
10.1093/ANNONC/MDH092
Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.
Y. Matsumura (2004)
10.1007/s11095-006-9132-0
Micellar Nanocarriers: Pharmaceutical Perspectives
V. Torchilin (2006)
10.1016/J.CBPA.2006.03.015
Aptamer therapeutics advance.
J. F. Lee (2006)
10.1021/NL052455Y
How to stabilize phospholipid liposomes (using nanoparticles).
L. Zhang (2006)
10.1073/pnas.0707461104
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
D. Bartlett (2007)



This paper is referenced by
TARGETED THERAPY FOR LIVER FIBROSIS AND CANCER
Y. Zhang (2014)
10.1021/bm201226x
Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells.
S. Mura (2011)
10.5772/21327
Radioisotopes and Nanomedicine
N. Sheets (2011)
10.1142/S179398441000016X
LIPID–POLYMER HYBRID NANOPARTICLES: SYNTHESIS, CHARACTERIZATION AND APPLICATIONS
Li I. Zhang (2010)
10.15407/UJPE58.01.0077
Nanophysics and Antiviral Therapy
V. Lysenko (2013)
10.1007/978-94-007-6028-8_4
Enhanced Vascular Permeability in Solid Tumors: A Promise for Anticancer Nanomedicine
Sebastien Taurin (2013)
10.1016/j.msec.2016.05.074
Recent advancements in nanotechnological strategies in selection, design and delivery of biomolecules for skin regeneration.
Purna Sai Korrapati (2016)
10.2174/1568026615666150701115508
Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines.
E. Zupančič (2016)
10.2174/138920012798356871
Tumour-specific uptake of anti-cancer drugs: the future is here.
M. Caraglia (2012)
10.1016/j.jconrel.2012.05.020
On the cellular processing of non-viral nanomedicines for nucleic acid delivery: mechanisms and methods.
D. Vercauteren (2012)
10.1081/E-EBPP-120050020
Anticancer Agents: Polysaccharide-Based Nanocarriers for Drug Delivery
Raje Chouhan (2015)
10.1007/978-3-030-01775-0_8
Delivery of Cancer Nanotherapeutics
Bomy Lee Chung (2019)
10.1016/J.PROCBIO.2017.08.021
Enzyme delivery using protein-stabilizing and cell-penetrating 30Kc19α protein nanoparticles
Hee Ho Park (2017)
10.1016/j.phrs.2010.03.005
Targeting nanoparticles to cancer.
M. Wang (2010)
10.1016/B978-0-323-41532-3.00013-0
Engineered nanoparticles as a precise delivery system in cancer therapeutics
R. Sharma (2016)
10.1533/9781908818782.267
Targeted gold nanoshells
Burapol Singhana (2015)
10.1007/S12668-012-0060-7
Nanotechnology as Emerging Tool for Enhancing Solubility of Poorly Water-Soluble Drugs
S. Kumar (2012)
10.1016/J.JLUMIN.2013.09.065
Studies on the effect of AgNP binding on α-amylase structure of porcine pancreas and Bacillus subtilis by multi-spectroscopic methods
Vinita Ernest (2014)
10.4032/9789814669849
Aptamer–Liposome Conjugates: Current Art and Future Prospects
O. Ries (2016)
10.15407/biotech12.06.012
CANCER DIAGNOSTICS, IMAGING AND TREATMENT BY NANOSCALE STRUCTURES TARGETING
Özcan Öznur Özge (2019)
10.1007/s11095-009-9897-z
Nanoparticulate Systems for Growth Factor Delivery
S. Zhang (2009)
10.1002/jbm.a.34607
PEG2000-DPSE-coated quercetin nanoparticles remarkably enhanced anticancer effects through induced programed cell death on C6 glioma cells.
G. Wang (2013)
10.1002/PPSC.201300158
pH-Responsive Theranostic Polymer-Caged Nanobins (PCNs): Enhanced Cytotoxicity and T1 MRI Contrast by Her2-Targeting.
B. Hong (2013)
10.1039/c8nr08790c
Non-invasive and quantitative in vivo monitoring of gold nanoparticle concentration and tissue hemodynamics by hybrid optical spectroscopies.
M. Mireles (2019)
10.1201/B14802
Nanoparticles in bioimaging
J. L. P. Ucha (2013)
10.1007/978-981-10-4702-2_9
Metallic Nanoparticles: Potential Antimicrobial and Therapeutic Agents
Pragati Jamdagni (2018)
10.5402/2012/571394
Targeted Delivery of Nanomedicines
V. Khanna (2012)
Nanotechnology: A novel approach towards cancer treatment
Rahul Goyal (2014)
10.1002/adhm.201700597
Atomic Force Microscopy as a Tool to Assess the Specificity of Targeted Nanoparticles in Biological Models of High Complexity
C. P. Gomes (2017)
10.1021/acsnano.5b03299
Nanomanufacturing: A Perspective.
J. Liddle (2016)
10.1016/j.bbagen.2013.01.021
Decreased reticuloendothelial system clearance and increased blood half-life and immune cell labeling for nano- and micron-sized superparamagnetic iron-oxide particles upon pre-treatment with Intralipid.
L. Liu (2013)
10.1002/smll.201001619
Advanced optical imaging reveals the dependence of particle geometry on interactions between CdSe quantum dots and immune cells.
J. Aaron (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar